A detailed history of Advisor Group Holdings, Inc. transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 11,872 shares of ADCT stock, worth $23,506. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,872
Previous 10,872 9.2%
Holding current value
$23,506
Previous $34,000 8.82%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.59 - $4.01 $2,590 - $4,010
1,000 Added 9.2%
11,872 $37,000
Q2 2024

Aug 13, 2024

BUY
$2.55 - $5.09 $7,323 - $14,618
2,872 Added 35.9%
10,872 $34,000
Q1 2024

May 10, 2024

SELL
$1.66 - $5.29 $9,960 - $31,740
-6,000 Reduced 42.86%
8,000 $35,000
Q4 2023

Feb 12, 2024

SELL
$0.47 - $1.79 $4,055 - $15,445
-8,629 Reduced 38.13%
14,000 $23,000
Q3 2023

Nov 13, 2023

BUY
$0.72 - $2.37 $8,254 - $27,172
11,465 Added 102.7%
22,629 $20,000
Q2 2023

Aug 10, 2023

BUY
$1.9 - $2.66 $3,195 - $4,474
1,682 Added 17.74%
11,164 $24,000
Q1 2023

May 12, 2023

BUY
$1.92 - $5.45 $5,564 - $15,794
2,898 Added 44.02%
9,482 $18,000
Q4 2022

Feb 10, 2023

BUY
$2.87 - $5.24 $3,808 - $6,953
1,327 Added 25.24%
6,584 $25,000
Q3 2022

Nov 14, 2022

SELL
$4.66 - $10.31 $1,053 - $2,330
-226 Reduced 4.12%
5,257 $25,000
Q2 2022

Aug 10, 2022

BUY
$5.96 - $14.99 $13,320 - $33,502
2,235 Added 68.81%
5,483 $44,000
Q1 2022

May 04, 2022

BUY
$13.28 - $20.03 $38,591 - $58,207
2,906 Added 849.71%
3,248 $47,000
Q3 2021

Nov 05, 2021

SELL
$20.45 - $30.0 $1,022 - $1,500
-50 Reduced 12.76%
342 $9,000
Q2 2021

Aug 02, 2021

BUY
$20.38 - $27.04 $4,300 - $5,705
211 Added 116.57%
392 $9,000
Q4 2020

Feb 10, 2021

BUY
$25.26 - $38.02 $404 - $608
16 Added 9.7%
181 $6,000
Q3 2020

Nov 12, 2020

SELL
$32.87 - $51.05 $460 - $714
-14 Reduced 7.82%
165 $5,000
Q2 2020

Aug 14, 2020

BUY
$29.65 - $46.81 $5,307 - $8,378
179 New
179 $8,000

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $154M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.